JP2006502243A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502243A5
JP2006502243A5 JP2005501197A JP2005501197A JP2006502243A5 JP 2006502243 A5 JP2006502243 A5 JP 2006502243A5 JP 2005501197 A JP2005501197 A JP 2005501197A JP 2005501197 A JP2005501197 A JP 2005501197A JP 2006502243 A5 JP2006502243 A5 JP 2006502243A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oligodeoxynucleotide
effective
use according
clusterin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005501197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502243A (ja
JP4620585B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2003/001276 external-priority patent/WO2004018675A1/en
Publication of JP2006502243A publication Critical patent/JP2006502243A/ja
Publication of JP2006502243A5 publication Critical patent/JP2006502243A5/ja
Application granted granted Critical
Publication of JP4620585B2 publication Critical patent/JP4620585B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2005501197A 2002-08-21 2003-08-21 クラステリンレベルを減少させることによる黒色腫の治療 Expired - Fee Related JP4620585B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40519302P 2002-08-21 2002-08-21
US40815202P 2002-09-03 2002-09-03
US31974802P 2002-12-02 2002-12-02
US47238703P 2003-05-20 2003-05-20
PCT/CA2003/001276 WO2004018675A1 (en) 2002-08-21 2003-08-21 Treatment of melanoma by reduction in clusterin levels

Publications (3)

Publication Number Publication Date
JP2006502243A JP2006502243A (ja) 2006-01-19
JP2006502243A5 true JP2006502243A5 (enExample) 2007-11-08
JP4620585B2 JP4620585B2 (ja) 2011-01-26

Family

ID=31950766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005501197A Expired - Fee Related JP4620585B2 (ja) 2002-08-21 2003-08-21 クラステリンレベルを減少させることによる黒色腫の治療

Country Status (16)

Country Link
US (1) US7285541B2 (enExample)
EP (1) EP1530636B1 (enExample)
JP (1) JP4620585B2 (enExample)
KR (1) KR101052289B1 (enExample)
AT (1) ATE478142T1 (enExample)
AU (1) AU2003258425B2 (enExample)
CA (1) CA2494764C (enExample)
CY (1) CY1110936T1 (enExample)
DE (1) DE60333839D1 (enExample)
DK (1) DK1530636T3 (enExample)
IL (1) IL166657A (enExample)
NO (1) NO333254B1 (enExample)
NZ (1) NZ538288A (enExample)
PT (1) PT1530636E (enExample)
SI (1) SI1530636T1 (enExample)
WO (1) WO2004018675A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2003062421A1 (en) 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
KR101117673B1 (ko) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
US7285541B2 (en) 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
MXPA06010667A (es) * 2004-03-19 2007-07-04 Penn State Res Found Metodos combinatorios y composiciones para el tratamiento de melanoma.
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
SI1814595T1 (sl) * 2004-11-23 2014-06-30 The University Of British Columbia Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
AU2006292293B2 (en) * 2005-09-19 2012-09-13 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
EP2190870A4 (en) * 2007-08-28 2010-12-01 Auckland Uniservices Ltd CELL MARKER OF MELANOCYTIC CELL LINE AND USE THEREOF
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
RU2013145869A (ru) 2011-03-15 2015-04-20 Дзе Юниверсити Оф Бритиш Коламбиа КОМБИНАЦИЯ ОЛИГОНУКЛЕОТИДА АНТИ-КЛАСТЕРИНА С ИНГИБИТОРОМ Hsp90 ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
AU2012328680A1 (en) 2011-10-25 2014-05-01 Ionis Pharmaceuticals, Inc. Antisense modulation of GCCR expression
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
US9937161B2 (en) 2013-03-06 2018-04-10 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
WO2014159775A1 (en) * 2013-03-14 2014-10-02 Teva Pharmaceutical Industries Ltd. Anti-clusterin monotherapy for cancer treatment
AU2023213987A1 (en) * 2022-01-26 2024-09-05 Idexx Laboratories, Inc. Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6111094A (en) * 1990-08-14 2000-08-29 Isis Pharmaceuticals Inc. Enhanced antisense modulation of ICAM-1
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
WO2000034469A1 (en) 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
NZ513757A (en) * 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
JP2003529554A (ja) 1999-12-21 2003-10-07 エール ユニヴァーシティ サバイビンによる血管形成の促進
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2003062421A1 (en) * 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
US7285541B2 (en) 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
KR101117673B1 (ko) * 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US8061408B2 (en) 2009-10-13 2011-11-22 Varel Europe S.A.S. Casting method for matrix drill bits and reamers

Similar Documents

Publication Publication Date Title
JP7116212B2 (ja) Ｌｐａの遺伝子発現の阻害のための組成物及び方法
CN113164509B (zh) 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
JP6649248B2 (ja) 細胞取り込みの向上のための化合物および方法
DK2850186T3 (en) COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
US20250270555A1 (en) Organic compositions to treat beta-catenin-related diseases
ES2657679T3 (es) Modulación del factor de expresión 11
AU2014306284B2 (en) Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
WO2013173637A1 (en) Compositions and methods for modulating gene expression
JP6487913B2 (ja) 成長ホルモン受容体のモジュレータ
CA2873769A1 (en) Compositions and methods for modulating hemoglobin gene family expression
KR20130106811A (ko) 근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법
JP2016513976A5 (enExample)
JP2018530325A (ja) アンジオテンシノーゲンの発現を調節するための化合物及び方法
JP6290316B2 (ja) ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2004509970A5 (enExample)
EA035756B1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
JP2010512747A5 (enExample)
JP2003531915A (ja) ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節
KR20080065617A (ko) 글루코코티코이드 수용체 발현의 조절
KR20150004414A (ko) Kras-관련 질환을 치료하기 위한 유기 조성물
TW202006138A (zh) Fubp1抑制劑用於治療b型肝炎病毒感染之用途
CN104011209A (zh) 病毒基因表达的抑制
CN110536965B (zh) 用于抑制男性型脱发靶基因表达的不对称siRNA
JP2008520591A5 (enExample)
CN121127248A (zh) 用于抑制线粒体偕胺肟还原组分1 (MARC1)表达的RNAi剂、其药用组合物及使用方法